For its wholly owned in vivo programs, Precision is developing an ARCUS nuclease that targets chronic hepatitis B covalently closed circular DNA. For its primary hyperoxaluria type 1 program ...

SHANGHAI, China I 19, 2024 I Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, ...

Preclinical data shows strong, durable, and precise repression of HBV DNA across in vitro and in vivo models, offering a possible pathway to a functional cure ...

Using a single primer, RCA generates hundreds of tandemly linked copies of a covalently closed circle in a few ... We used two different pre-formed circular DNA templates for RCA signal coding ...